Jason Levin’s career can be read as a study in decreasing distance from risk. At ALZA Corporation, he worked inside an established drug-delivery business. At Jazz Pharmaceuticals, which he joined in 2003 as one of its initial employees, the organization was younger and the outcomes less settled. Chief business officer roles at BrainCells and Sorbent Therapeutics put him closer still to the decisions that decide whether an experimental program becomes a company or a footnote.
Then, in 2012, he co-founded Orbus Therapeutics with Bob Myers. The distance largely disappeared. Orbus was a small, private biopharmaceutical company with a narrow purpose: develop products for rare diseases with few effective options. In practice, the company concentrated its effort around eflornithine, an oral drug candidate that inhibits an enzyme involved in polyamine production. The molecule became a company-sized wager.
There is little glamour in the middle of such a wager. A trial protocol does not care about a founder’s charisma. Manufacturing, patents, site recruitment, follow-up and capital arrive as separate problems, usually before the previous one has politely left. Levin spent years as Orbus’s chief operating officer, a title that describes the part of entrepreneurship conducted in spreadsheets, contracts and calendars.
The apprenticeship in company building
Levin’s education points toward translation rather than laboratory specialization: a BA from the University of California, San Diego, followed by an MBA from the University of Texas at Austin’s McCombs School of Business. His operating education came through companies that sat at different stages of pharmaceutical life.
ALZA showed what drug development looks like with corporate machinery behind it. Jazz offered the early-company version. Levin served as vice president of corporate development there, one of the people responsible for connecting assets, capital and strategy. BrainCells, focused on central nervous system drug discovery, and Sorbent, developing oral polymers, each put him in the chief business officer seat. By the time Orbus began, he had spent years learning the peculiar bilingualism of biotech: enough science to understand the claim, enough business to understand what proving it will cost.
That translation work was visible outside the boardroom. Levin is a named co-author on a 2020 peer-reviewed paper examining eflornithine in temozolomide-treated cells. He also appears as a co-inventor on patent filings assigned to Orbus. Neither fact turns a business executive into a bench scientist. Together, they show an operator staying close to the technical substance of the asset his company was built to advance.
A trial meets a new dictionary
Orbus began the Phase 3 STELLAR study in 2016. The design compared eflornithine plus lomustine with lomustine alone in people whose tumors had returned after prior treatment. It was a large undertaking for a compact company: 343 participants, 74 sites and eight countries. The primary endpoint was overall survival.
The broad result needs to be stated first. Across the full intention-to-treat population, the trial did not show a difference in survival. Median overall survival was 23.4 months for the combination and 20.3 months for lomustine alone, with a hazard ratio of 0.94. The primary endpoint was not met.
While the study was running, the scientific vocabulary changed. The World Health Organization’s 2021 classification of central nervous system tumors incorporated molecular features more fully. Tumors grouped together under the older 2016 rules no longer necessarily belonged in the same category. A study population assembled under one map could be examined with a more precise one.
How to read the STELLAR result
One trial, two clearly separated findings
Median overall survival: 23.4 months with the combination versus 20.3 months with lomustine alone.
Median overall survival: 34.9 months with the combination versus 23.5 months with lomustine alone.
Before the study was unblinded, the team defined a subset aligned with the newer classification: 196 participants with IDH-mutant, grade 3 astrocytoma. In that group, median overall survival was 34.9 months with the combination and 23.5 months with lomustine alone. Median progression-free survival was 15.8 months versus 7.2 months. The Journal of Clinical Oncology paper called these clinically meaningful improvements and reported that no benefit was observed in grade 4 tumors.
“These data, while taken from a subset analysis, represent one of the first meaningful advances for a patient population.”Jason Levin, November 2025
The phrase “while taken from a subset analysis” is doing honest work. Levin is advocating for the finding without pretending the full trial succeeded. Biotech communication often goes wrong when the qualifying clause is treated as an inconvenience. Here it is central. The Orbus case is compelling precisely because the evidence has edges.
The handover after thirteen years
In February 2025, Orbus announced that Myers would step away from day-to-day executive work and Levin would become president. Levin’s response was revealing in its allocation of credit. He pointed to Myers’s role in building the company and securing the funding that allowed STELLAR to finish. Founder transitions can invite a brisk rewriting of history. Levin instead named the predecessor and the work.
By November, Orbus was identifying Levin as president and chief executive officer. The timing placed him in charge at the least tidy stage of the story. Enrollment was finished. The data had been analyzed. Updated results were presented at the Society for Neuro-Oncology annual meeting, followed by publication in December 2025. Yet publication is not approval, and a subgroup finding is not a commercial product.
A network built across old rooms
Orbus also illustrates how a career compounds through people. Myers and Levin had both worked at Jazz. Several members of the Orbus leadership group came through ALZA or Jazz as well. Noymi Yam, the company’s chief scientific officer, had experience at both ALZA and Sorbent. Jennifer Ekelund, who leads regulatory affairs and quality assurance, spent years at ALZA and Jazz. These are not random résumé overlaps. In a small company, prior knowledge of how colleagues think can replace layers of process that a larger organization would take for granted.
The board added another circle of institutional memory. Longitude Capital, Adams Street Partners, H.I.G. and Abingworth were connected to Orbus through directors or financing. Some of those relationships reached back to Jazz. The pattern resembles a carefully assembled relay team: operating experience from earlier companies, scientific depth from clinical advisers, and investors familiar with the long timelines of pharmaceutical development.
Levin’s public comments tend to distribute credit across that network. When the leadership change was announced, he emphasized Myers’s work. When Orbus discussed the updated trial data, the company pointed to the investigators, the conference presentation and the peer-reviewed publication. This is more than good manners. Drug development is structurally collective. A founder can set priorities and negotiate the next step, but no founder personally enrolls patients across 74 sites, adjudicates scans, manufactures supply and performs every analysis. The operating achievement lies in making those separate contributions arrive in the right order.
Levin’s stated next move is collaborative rather than theatrical: work with the FDA and other regulatory authorities to identify a path forward. Orbus has also said it is seeking corporate partners for development and commercialization. These are practical ambitions. They require a case sturdy enough for scientific scrutiny, a manufacturing plan, regulatory agreement and capital. The finish line, if one exists, is still some distance away.
State the overall result and the subgroup result separately. Precision earns more trust than a polished blur.
STELLAR ran across years, sites and changing scientific definitions. The organization had to survive all three.
Levin’s research authorship and patent work kept the business role connected to the asset itself.
When leadership changed, Levin publicly recognized the financing and company-building work that came before him.
What endurance is for
Persistence is often sold as a personality trait, as though staying at the table guarantees dessert. Drug development is less sentimental. Endurance matters only when it produces better information and preserves the ability to act on it. Orbus remained in place long enough to complete a multinational trial, absorb a change in classification, publish the result and ask a more exact question of regulators.
Levin’s career makes that process visible. He is neither the discoverer alone at the bench nor the celebrity founder selling a future in broad strokes. His public record is the record of an operator: business-development roles, company formation, financing, patents, trial execution, succession and a carefully qualified argument about evidence.
The useful practice to steal is disciplined continuity, a sturdier discipline than stubbornness. Keep the team alive. Keep the data interpretable. Update the map when the field learns something new. Say where the result holds and where it does not. Then carry the narrower, stronger claim into the next room.
For Jason Levin, that next room is likely to contain regulators and potential partners rather than a confetti cannon. A decade-plus wager has yielded a published finding, an asterisk that must remain attached, and a concrete next question. In biotechnology, that can be enough work for one career chapter - and enough uncertainty to begin another.